Politiparty
Politiparty

118th Congress Health

H.R. 7188: Shandra Eisenga Human Cell and Tissue Product Safety Act

Passed HouseDec 16, 2024

  1. Passed House (completed)Dec 16, 2024
  2. Passed Senate (not reached)
  3. To the President (not reached)
  4. Became law (not reached)

Summary

Reported to House, Nov 22, 2024

This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.

Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments.

The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

1

Bipartisan support.

Who scored on this bill

72 points earned
  1. 1John Moolenaar R-MI SponsorDrew cross-party cosponsors, introduced, marked up, reported, passed House5 events+68
  2. 2Debbie Dingell D-MICosponsored; cosponsored bill passed2 events+4
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by John Moolenaar

History

  1. Dec 16, 2024Passed the House by voice vote.
  2. Feb 1, 2024Introduced in the House by John Moolenaar.
Show the full action history (16 actions)
  1. Dec 17, 2024Received in the Senate.
  2. Dec 16, 2024Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
  3. Dec 16, 2024Considered under suspension of the rules. (consideration: CR H7167-7170)
  4. Dec 16, 2024DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
  5. Dec 16, 2024Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
  6. Dec 16, 2024On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
  7. Dec 16, 2024Motion to reconsider laid on the table Agreed to without objection.
  8. Nov 22, 2024Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
  9. Nov 22, 2024Placed on the Union Calendar, Calendar No. 632.
  10. Sep 18, 2024Committee Consideration and Mark-up Session Held
  11. Sep 18, 2024Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
  12. May 16, 2024Subcommittee Consideration and Mark-up Session Held
  13. May 16, 2024Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
  14. Feb 2, 2024Referred to the Subcommittee on Health.
  15. Feb 1, 2024Introduced in House
  16. Feb 1, 2024Referred to the House Committee on Energy and Commerce.